Sarafem patent upheld
D.C. federal appeals court upholds Sarafem (fluoxetine) use patent as valid and infringed by Teva's ANDA in a July 13 FDL-1ruling. The premenstrual dysphoric disorder product, a repackaged version of Prozac, was launched by Lilly in August 2000; the company divested it to Galen/Warner Chilcott in 2002 (1"The Pink Sheet" Dec.16, 2002, p. 34). The appellate court rejected Teva's arguments that the Indianapolis district court erred by construing the patent claim to include dosing regimens "that go on continuously." The court also disagreed with Teva's argument that the lower court improperly ruled the patent invalid for reasons of obviousness (2"The Pink Sheet" Aug. 23, 2004, In Brief)...
You may also be interested in...
Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly
Increasing clinical trial complexity goes hand in hand with increased reliance on advanced-analysis software. Raj Indupuri of eClinical Solutions believes the company's product will lead this emerging market.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.